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The prevalence of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) is 1.3% in pub-
lished studies. Clinical associations include high-inoculum infections and glycopeptide failure, with hVISA
infections associated with a 2.37-times-greater failure rate (95% confidence interval [CI], 1.53 to 3.67) com-
pared to vancomycin-sensitive Staphylococcus aureus (VSSA) infections. Despite this, 30-day mortality rates
were similar to those for VSSA infections (odds ratio [OR], 1.18; 95% CI, 0.81 to 1.74). The optimal therapy
for hVISA requires further study.
In the presence of selection pressure, vancomycin-suscepti-
ble Staphylococcus aureus (VSSA) isolates are able to trans-
form their cell wall and become less susceptible to vancomycin
(51). These vancomycin-intermediate S. aureus (VISA) isolates
are defined by a vancomycin broth microdilution MIC of 4 to
8 g/ml (57) and may progress through a precursor phenotype
known as heteroresistant vancomycin-intermediate Staphylo-
coccus aureus (hVISA) (11). Although the precise definition is
disputed, heteroresistance refers to the presence of a resistant
subpopulation (typically at a frequency of 105 to 106
CFU) in a fully susceptible isolate (a broth microdilution MIC
of 2 g/ml).
Detection. hVISA detection is problematic, as commercial
susceptibility platforms use inocula lower than the required
threshold. As a consequence, multiple screening and detection
methods using higher inocula and growth promotion of resis-
tant subpopulations have been developed. Controversy re-
mains, as some of these methods may select for resistant sub-
populations in vitro rather than detect the in vivo presence of
heteroresistance (60). The most accurate and reproducible
method is the modified population analysis profile (PAP)-area
under the curve (AUC), which utilizes the plot of the number
of viable colonies against vancomycin concentration. An AUC
ratio of the test strain to the reference strain (Mu3) of 0.9
confirms an hVISA isolate. However, PAP-AUC use is limited
as it is expensive and labor- and time-intensive.
Epidemiology. Following the first documented VISA
(Mu50) and hVISA (Mu3) strains from Japan (22, 23), both
phenotypes have been reported worldwide. The precise burden
of hVISA is difficult to determine given the range of testing
methodologies, definitions, and changes in vancomycin suscep-
tibility breakpoints in 2006. This may explain the marked vari-
ation in hVISA prevalences detected across institutions, geo-
graphical regions, and patient populations, with surveillance
studies generally confirming lower hVISA rates than those for
selected clinical isolates. Nevertheless, the overall hVISA prev-
alence remains low at approximately 1.3% of all methicillin-
resistant S. aureus (MRSA) isolates tested (Table 1) (1–6, 8, 9,
12–16, 18–20, 22, 24, 29–39, 41–47, 49, 50, 52, 55, 56, 58, 61).
Clinical significance of hVISA. All English-language studies
containing the term S. aureus and any of the terms reduced
susceptibility, intermediate susceptibility, and heteroresistance
or heteroresistant to vancomycin or glycopeptides were iden-
tified through Medline (2006 to 2010) and reviewed. All arti-
cles with clinical details are summarized in Table 2 (2, 4, 5, 8,
16, 24, 28, 31, 33, 37, 38, 41). Considerable heterogeneity exists
between studies due to the differing patient populations stud-
ied, testing methodologies used, and MRSA isolates selected
(i.e., initial blood culture compared to final isolate). Despite
this, high-inoculum infections (such as infective endocarditis,
osteomyelitis, deep abscesses, and prosthetic device infections)
(8, 16, 37) and vancomycin treatment failure (defined as per-
sistent infection or bacteremia duration and/or ongoing signs
of infection) (2, 4, 8, 16, 42) were common associations with
hVISA infection. After the available data were pooled, the
odds of glycopeptide failure were 2.37 times greater for hVISA
than for VSSA infections (odds ratio [OR], 2.37; 95% confi-
dence interval [CI], 1.53 to 3.67) (Fig. 1). Since high-inoculum
infections are independently associated with bacteremic per-
sistence (therapeutic failure) (10, 17, 31) and de novo hVISA
infections do not always result in treatment failure, hVISA may
reflect the consequence rather than the cause of treatment
failure.
Intuitively, persistent bacteremia should result in greater
morbidity. However, compared to VSSA infections, hVISA
persistence does not lead to more metastatic complications
(41). Other parameters of morbidity have not been extensively
examined. A significant increase in the mean hospital stay in
patients with hVISA infection has been documented in one
study (16). Similarly, infection-related complications are gen-
erally not reported (secondary to the heterogeneity of the
principal diagnosis) except for one study where hVISA infec-
tive endocarditis patients were more likely to develop conges-
tive cardiac failure (4).
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Significance of MIC in hVISA. The proportion of hVISA
detected is directly related to increases in vancomycin MIC
with the majority (80%) of hVISA isolates demonstrating an
Etest MIC of2 g/ml (41). Although a detailed discussion of
the clinical significance of higher MICs is beyond the scope of
this review, several studies have documented greater mortality
associated with higher-MIC-susceptible MRSA isolates (gen-
erally between 1.5 and 2 g/ml) (21, 53). Only one study has
examined both variables (vancomycin MIC and heteroresis-
tance phenotype) in the same isolates, with neither variable
predictive of overall mortality on multivariate analysis (41).
Thus, the relative contribution of heteroresistance to MIC-
related outcomes remains unclear and requires further study.
Mortality and hVISA. Since hVISA is associated with pa-
rameters known to influence mortality (i.e., high-inoculum in-
fections, persistent bacteremia, and high vancomycin MICs),
one would expect an increased mortality compared to that of
VSSA infections (Table 2). However, no study to date has had
the power to detect such a difference. After all available data
from comparative studies were pooled, hVISA was associated
with a 30-day mortality rate similar to that of VSSA infections
(OR, 1.18; 95% CI, 0.81 to 1.74) (Fig. 2). These findings can in









No. (%) of hVISA
isolates detected
No screening test Macromethod Etest Israel (37, 38) Blood 487 43 (8.8)
Singapore (16) Blood 56 3 (5.4)
USA (41) Blood 489 71 (14.5)
PAP-AUC Australia (8, 24) Blood/any 170 64 (37.6)
World (4) Blood 65 19 (29.2)
Japan (42) Blood 20 2 (10)
Simplified PAP USA (14, 45, 56) Blood 738 3 (0.4)
Europe (50) Any 302 0 (0)
Germany (20) Any 85 7 (8.2)
Simplified PAP PAP Asia (52) Any 1,357 58 (4.3)
Spain (2) Device related 19 14 (73.7)
Japan (22, 29) Any 7,774 35 (0.5)
Korea (32, 33) Any 4,045 24 (0.6)
Germany (6) Any 367 2 (0.5)
Variation of simplified PAP PAP Greece (30) Any 72 1 (1.4)
Italy (39) Any 179 2 (1.1)
Thailand (36, 58) Any 1,049 15 (1.4)
France (44) Any 171 2 (1.2)
Mexico (12) Any 152 1 (0.7)
Belgium (13) Any 2,145 4 (0.2)
Macromethod Etest PAP USA (35) Any 982 2 (0.2)
PAP-AUC USA (46, 47) Blood/any 3,299 140 (4.2)
Ireland (15) Any 3,189 73 (2.3)
UK (34) Blood/nasal 2,550 86 (3.4)
Canada (1) Any 475 25 (5.3)
Screening agar PAP Turkey (49) Any 256 46 (18)
Belgium (43) Nasal/skin 455 3 (0.7)
Korea (9) Any 37,856 18 (0.1)
PAP-AUC France (19) Any 2,300 255 (11.1)
China (55) Any 200 26 (13)
USA (31) Blood 22 3 (13.6)
Simplified PAP France (5) Any 48 13 (27.1)
MIC based UK (3) Any 11,242 0 (0)
Hong Kong (61) Blood 52 3 (5.8)
MIC based PAP USA (18) Blood 30 0 (0)
Total 82,698 1,063 (1.3)
a Screening and/or confirmation testing included the following tests. For a more detailed discussion on the performance of each test, see reference 25. Simplified
population analysis profile (PAP): growth of (1 to 30) colonies on brain heart infusion agar supplemented with 4 mg/liter vancomycin at 48 h is considered positive for
hVISA. Variations of simplified PAP include using different inoculum sizes (10 l), inoculum concentrations (0.5 McFarland standard), media (Mueller-Hinton
agar), antibiotics (teicoplanin), and/or vancomycin concentrations (3 or 6 mg/liter). PAP: hVISA is present when the graph of isolated colonies on brain heart infusion
agar or Mueller-Hinton agar plotted against increasing vancomycin concentration at 48 h is similar to that for the reference (Mu3) strain. Analysis can be standardized
using the area under the curve (PAP-AUC) with hVISA being confirmed when the ratio of the test strain to the control strain (Mu3) is between 0.9 and 1.3.
Macromethod (2 McFarland standard) Etest on brain heart infusion agar is defined as positive for hVISA if the vancomycin and teicoplanin MICs are 8 g/ml or
the teicoplanin MIC is 12 g/ml for the isolate. Screening agars: 1 colony isolated after 24 to 48 h on either brain heart infusion agar or Mueller-Hinton agar
supplemented with vancomycin or teicoplanin is considered positive for hVISA. MIC-based testing includes standard Etest or vancomycin broth microdilution of
resistant subpopulations.




























































































































































































































































































































































































































































































































































































































































































































































































































































































part be explained by the reduced virulence and decreased host
immune responses demonstrated in animal infection models
and laboratory studies with hVISA infections (27, 40). A clin-
ical study indirectly supports this link, with hVISA significantly
more likely to be associated with colonization rather than in-
fection (24).
Conclusion and therapeutic implications. The role of van-
comycin in the treatment of hVISA remains unclear, as het-
eroresistance may emerge during glycopeptide therapy, espe-
cially in infections associated with poor antibiotic penetration
(infective endocarditis and osteomyelitis) (8). Despite these
deficiencies, no new antibiotic has been documented to be
superior to vancomycin (17). Alternative agents have been
used successfully in numerous case reports (25). However,
potential concerns remain when prescribing these agents.
These include toxicity with prolonged linezolid use (7), possi-
ble cross-resistance with lipoglycopeptides (54), and the clini-
cal relevance of emerging low-level daptomycin nonsuscepti-
bility during treatment of hVISA infections (48). An important
adjunct to antimicrobial therapy and a key component of suc-
cess is surgical debridement for high-inoculum hVISA infec-
tions (26). Irrespective of treatment choice, MRSA bacteremia
mortality remains high (59). Therefore, further research
should be aimed at developing new agents and defining the
optimal pharmacodynamic parameters of current antibiotics,
including vancomycin, in targeting specific clinical contexts.
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